CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period
DOI 10.1055/s-0036-1587175
Bibliografische Angaben
Nachweis in CareLit
Autor:innenD Hörsch, M Kulke, ME Caplin, LB Anthony, E Bergsland, K Öberg, S Welin, RP Warner, C Lombard-Bohas, PL Kunz, E Grande, JW Valle, D Fleming, P Lapuerta, S Jackson, B Zambrowicz, AT Sands, M Pavel
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: TELESTAR was a pivotal, randomized phase 3 study evaluating telotristat etiprate (TE), a tryptophan hydroxylase inhibitor, among patients (pts) with carcinoid syndrome (CS). When added to somatostatin analogues (SSA), 250 mg tid and 500 mg tid TE each produced significantly greater bowel movement (BM) frequency reduction averaged over 12 weeks (wks) than placebo (PBO) plus SSA (p < 0.001). Pts crossed…
Zitieren
Zitierempfehlung
D Hörsch, M Kulke, ME Caplin, LB Anthony, E Bergsland, K Öberg, S Welin, RP Warner, C Lombard-Bohas, PL Kunz, E Grande, JW Valle, D Fleming, P Lapuerta, S Jackson, B Zambrowicz, AT Sands, M Pavel (2016) Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0036-1587175
Mit CareLit weiterarbeiten